SCHEMBL7713428

SCHEMBL7713428

C[C@]12CC[C@H]3[C@@H](CC=C4NC(=O)CC(OC5CC5)[C@@]43C)[C@@H]1CCC2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TSHR P16473 2/20 0.48
LMNA P02545 2/20 0.48
PMP22 Q01453 2/20 0.48
BLM P54132 1/20 0.48
MEN1 O00255 1/20 0.48
SHBG P04278 1/20 0.48
SERPINA6 P08185 1/20 0.48
GUSB P08236 1/20 0.48
G6PD P11413 1/20 0.48
KMT2A Q03164 1/20 0.48
GPBAR1 Q8TDU6 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
ABCC4 O15439 1/20 0.47
CYP19A1 P11511 9/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7713246 0.89 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19TDP1TSHR
SCHEMBL7713430 0.76 CYP19A1 (0.50) CYP3A4CYP2C9CYP2C19TDP1TSHR
SCHEMBL7529519 0.76 CYP19A1 (0.58) CYP3A4TSHRLMNAPMP22MEN1
SCHEMBL3797856 0.76 CYP19A1 (0.58) CYP3A4TSHRLMNAPMP22MEN1
SCHEMBL10274355 0.74 CYP19A1 (0.66) CYP3A4TSHRLMNAPMP22MEN1
SCHEMBL7611395 0.72 SRD5A1 (0.57) CYP3A4CYP2C9CYP2C19TSHRLMNA
SCHEMBL7611390 0.72 SRD5A1 (0.57) CYP3A4CYP2C9CYP2C19TSHRLMNA
SCHEMBL8715293 0.71 CYP19A1 (0.44) CYP3A4LMNAPMP22MEN1SHBG
SCHEMBL10934115 0.69 CYP3A4 (0.74) CYP3A4CYP2C9CYP2C19TDP1TSHR
SCHEMBL10934103 0.69 CYP3A4 (0.74) CYP3A4CYP2C9CYP2C19TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365597-B1 FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE AVENTIS PHARMACEUTICALS INC. 2002-04-02 US disclosed
EP-0880540-A1 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE HOECHST MARION ROUSSEL, INC. (US) 1998-12-02 EP disclosed
WO-1997030069-A1 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE HOECHST MARION ROUSSEL, INC. (US) 1997-08-21 WO disclosed